The Europe peptide therapeutics CDMO market size was estimated at USD 880.00 million in 2025 and is projected to be worth around USD 2,388.39 million by 2035, expanding at a CAGR of 10.50% from 2026 to 2035. Growing due to expanding pharmaceutical manufacturing capabilities and rising focus on innovative drug production.

Europe Peptide Therapeutics CDMO Market Statical Scope

With the pharmaceutical industry's increasing need for biologics, antibody-drug conjugates, and customized medications, the European therapeutics CDMO market is growing. To comply with environmental regulations, CDMO providers are making investments in energy-efficient production technologies and sustainable manufacturing facilities. To improve regional service networks, pharmaceutical manufacturers are increasingly forming strategic alliances for mergers and acquisitions. Additionally, growing outsourcing of clinical manufacturing and complex drug development tasks keeps the market expanding.

Growing pharmaceutical innovation and increased production of complex therapeutics are driving the therapeutics CDMO market in Europe. Strict regulatory standards throughout the region are pushing pharmaceutical companies to collaborate with seasoned CDMOs for quality compliance and manufacturing efficiency; increasing investments in advanced biologics manufacturing and sustainable production facilities are also driving market expansion. Pharmaceutical businesses are being encouraged to collaborate with seasoned CDMOs for manufacturing efficiency and quality compliance due to the region's strict regulations. The market is growing because of increased expenditures in sophisticated biologics manufacturing and sustainable production facilities.

Europe Peptide Therapeutics CDMO Market Share, By Synthesis Method, 2025 (%)

• Solid-Phase Peptide Synthesis (SPPS): Solid phase peptide synthesis dominated the market in 2025 with a market share of 34% fueled by the growing need for high purity therapeutic peptides and their widespread use in commercial peptide production. The market was further bolstered by technological developments in automated peptide synthesizers.
• Liquid-Phase Peptide Synthesis (LPPS): Liquid-phase peptide synthesis (LPPS) segment was the fastest growing in the market with a share of 11% driven by increased emphasis on economical peptide synthesis techniques and increased manufacturing flexibility. Segment expansion was also aided by expanding industrial scale applications.

Europe Peptide Therapeutics CDMO Market Share, By Service Type, 2025 (%)

• API development & manufacturing: API development & manufacturing segment dominated the market in 2025 with a market share of 22% driven by growing production demand from pharmaceutical companies and an increase in the outsourcing of peptide APIs. The segment was also aided by the expansion of peptide manufacturing facilities throughout Europe.
• Process development & optimization: Process development & optimization segment was the fastest growing in the market with a share of 14%, driven by the growing focus in peptide production on process effectiveness, quality improvement, and regulatory compliance. Growth was further accelerated by the adoption of sophisticated analytical technologies.

Europe Peptide Therapeutics CDMO Market Share, By Peptide Type, 2025 (%)

• Generic peptide: Generic peptide segment was the fastest growing in the market with a share of 19% driven by the growing demand for less expansive therapeutic alternatives and the growing availability of generic peptide medications. Market expansion was further aided by advantageous regulatory pathways.
• Innovative/Novel Peptides: Innovative/novel peptides segment dominated the market in 2025 with a market share of 22% fueled by growing research partnerships and increased investments in cutting edge peptide treatments. Expanding the segment was further reinforced by the growing emphasis on personalized medicine.

Europe Peptide Therapeutics CDMO Market Share, By Application Area, 2025 (%)

• Oncology & Cancer Treatment: Oncology & cancer segment dominated the market in 2025 with a market share of 24% fueled by the growing use of peptide therapeutics for targeted drug delivery and the rising incidence of cancer. The segments position was further reinforced by rising investments in the development of peptide drugs targeted at cancer.
• Diabetes & Metabolic Disorders: Diabetes & metabolic disorders segment was the fastest growing in the market share of 18% fueled by an increase in peptide based GLP 1 treatments and diabetes cases. Growing knowledge about managing metabolic diseases also aided in the expansion of the market.

Europe Peptide Therapeutics CDMO Market Share, By Scale of Operation, 2025 (%)

• Research & Development Scale: Research & development scale segment was the fastest growing in the market with a share of 18% driven by growing funding for early-stage therapeutic innovation and peptide discovery initiatives. Demand was further accelerated by growing partnerships between CDMOs and biotech companies.
• Clinical Trial Manufacturing: Clinical trials manufacturing segment dominated the market in 2025 with a market share of 20% driven by a rise in the outsourcing of trial scale manufacturing activities and the number of peptide drug candidates entering clinical pipelines. The segment's growth was further aided by an increase in regulatory approvals for experimental peptide treatments.

Europe Peptide Therapeutics CDMO Market Share, By End User Type, 2025 (%)

• Large Pharmaceutical Companies: Large pharmaceutical companies segment dominated the market in 2025 with a market share of 31% driven by significant outsourcing costs growing commercialization efforts for peptide drugs and a strong emphasis on growing biologics portfolios. Segment of dominance was further reinforced by long standing relationships with CDMOs.
• Biotechnology Companies: The Biotechnology companies segment was the fastest growing in the market with a share of 24%, driven by expanding funding for new biotech companies and growing innovation in peptide therapeutics. Growth was also influenced by a growing reliance on specialized CDMO services.

Competitive Landscape

The Europe therapeutics CDMO market is characterized by strong competition among established pharmaceutical manufacturers and specialized biologics CDMO providers. Companies are focusing on sustainable manufacturing practices, advanced biologics production, and expansion of high-potency API capabilities. Partnerships with research organizations and investments in innovative therapeutic manufacturing are further shaping the competitive landscape. Key companies in the market include Lonza, Recipharm, Siegfried Holding AG, Boehringer Ingelheim, Rentschler Biopharma, and Fareva.

Segments Covered in the Report

By Synthesis Method

• Solid-Phase Peptide Synthesis (SPPS)
• Liquid-Phase Peptide Synthesis (LPPS)
• Hybrid/Mixed-Phase Synthesis
• Recombinant Peptide Production
• Chemical Synthesis Methods
• Enzymatic Synthesis Approaches
• Fragment Condensation Techniques
• Convergent Synthesis Strategies

By Service Type

• API Development & Manufacturing
• Process Development & Optimization
• Analytical Method Development & Validation
• Regulatory Affairs & CMC Support
• Formulation Development
• Fill-Finish & Packaging Services
• Quality Control & Assurance
• Clinical Trial Material Manufacturing
• Commercial Manufacturing
• Technology Transfer Services

By Peptide Type

• Generic Peptides
• Innovative/Novel Peptides
• Modified Peptides (PEGylated, Lipidated)
• Cyclic Peptides
• Stapled Peptides
• Peptide-Drug Conjugates (PDCs)
• Antimicrobial Peptides
• Hormonal Peptides
• Therapeutic Proteins & Peptides
• Cosmetic & Nutraceutical Peptides

By Application Area

• Oncology & Cancer Treatment
• Diabetes & Metabolic Disorders
• Cardiovascular Diseases
• Central Nervous System Disorders
• Infectious Diseases
• Autoimmune & Inflammatory Conditions
• Hormonal Therapies
• Pain Management
• Dermatology & Cosmetics
• Gastrointestinal Disorders

By Scale of Operation

• Research & Development Scale
• Clinical Trial Manufacturing
• Pilot Scale Production
• Commercial Scale Manufacturing
• Large-Scale Industrial Production
• Custom Small Batch Production

By End-User Type

• Large Pharmaceutical Companies
• Biotechnology Companies
• Academic & Research Institutions
• Government Research Organizations
• Clinical Research Organizations (CROs)
• Specialty Pharmaceutical Companies
• Generic Drug Manufacturers
• Cosmetic & Nutraceutical Companies